PT-141 (Bremelanotide) research guide for Kitami. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
Research-Grade PT-141 (Bremelanotide) for Kitami Investigators
PT-141 (Bremelanotide) won't be found on pharmacy shelves in Kitami or most other cities — this is a specialist compound supplied via a dedicated online market. What this means for Kitami researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are accessible to anyone. Separating quality PT-141 (Bremelanotide) from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Kitami researchers need to know about finding, evaluating, and storing PT-141 (Bremelanotide) for scientific research use.
The Science Behind PT-141 (Bremelanotide)
The melanocortin receptor family (MC1R through MC5R) mediates a diverse range of physiological functions, and research peptides like Melanotan-2 and PT-141 (Bremelanotide) act on different receptor subtypes with different research applications. MT-2 has broad melanocortin receptor activity and has been studied for pigmentation (MC1R), appetite suppression (MC4R), and other endpoints. PT-141 is a more specific MC3R/MC4R agonist studied primarily for CNS-mediated effects. For researchers in Kitami designing experiments with PT-141 (Bremelanotide), the specific receptor binding profile determines which outcomes are mechanistically attributable to the compound and which require additional explanation.
PT-141 (Bremelanotide) Purchasing Guide
Assessing PT-141 (Bremelanotide) vendors starts with the COA: access the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA establishes that the main HPLC peak is actually PT-141 (Bremelanotide) and not a structurally similar impurity — HPLC purity alone provides no identity confirmation. Signs of a credible vendor beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and shipping with desiccant and appropriate cold protection. For Kitami researchers making a first PT-141 (Bremelanotide) purchase: work through this evaluation framework first, begin with a small order, and verify batch traceability on arrival before use.
Order PT-141 (Bremelanotide) — ships to Kitami
COA-verified · International tracking · Research grade
PT-141 (Bremelanotide) Safety, Handling & Research Protocols
PT-141 (Bremelanotide) is available for research use only and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is educational. Storage requirements for PT-141 (Bremelanotide): lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bacteriostatic water. Quality PT-141 (Bremelanotide) sourcing is not separable from research safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that rigorous vendor evaluation eliminates. Protocol documentation — documenting product details, dates, and administration precisely — is a sound practice for any PT-141 (Bremelanotide) protocol that ensures unusual findings can be explained.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
